Sanofi-Product Pipeline Review-2015

Sanofi-Product Pipeline Review-2015

  • Products Id :- GMDHC06990CDB
  • |
  • Pages: 204
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sanofi-Product Pipeline Review-2015


Global Markets Direct's, 'Sanofi-Product Pipeline Review-2015', provides an overview of the Sanofi's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sanofi's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Sanofi including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Sanofi's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Sanofi's pipeline products

Reasons To Buy

Evaluate Sanofi's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Sanofi in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Sanofi's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Sanofi and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sanofi

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Sanofi and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sanofi Snapshot 6

Sanofi Overview 6

Key Information 6

Key Facts 6

Sanofi-Research and Development Overview 7

Key Therapeutic Areas 7

Sanofi-Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products-Monotherapy 15

Pipeline Products-Combination Treatment Modalities 16

Pipeline Products-Partnered Products 17

Pipeline Products-Out-Licensed Products 19

Sanofi-Pipeline Products Glance 21

Sanofi-Late Stage Pipeline Products 21

Sanofi-Clinical Stage Pipeline Products 24

Sanofi-Early Stage Pipeline Products 27

Sanofi-Drug Profiles 30

(fluticasone propionate + formoterol fumarate) 30

Toujeo 32

mipomersen sodium 34

semuloparin 36

(fexofenadine hydrochloride + phenylephrine hydrochloride) 37

(insulin glargine + lixisenatide) 38

cabazitaxel 40

encephalitis vaccine 42

insulin lispro 44

lixisenatide 45

tetanus + diphtheria + pertussis (acellular) vaccine 48

fexinidazole 49

alemtuzumab 51

coltuximab ravtansine 54

ferroquine 56

isatuximab 57

plerixafor 59

SAR-125844 61

SAR-156597 62

vatelizumab 63

VerorabVax 64

GZ-389988A 65

pilaralisib 66

SAR-408701 69

SAR-421869 70

SAR-422459 71

voxtalisib 72

AVE-8112 74

SAR-113244 75

SAR-228810 76

SAR-252067 77

SAR-405838 78

SAR-405838 + pimasertib hydrochloride 79

SAR-425899 80

SAR-566658 81

ACP-002 83

ACP-003 84

ACP-004 85

AVE-3085 86

BSI-401 87

cyclohexylgriselimycin 88

Drugs for Type 1 Diabetes 89

food allergy vaccine 90

LCB-17 91

MI-51964 92

Monoclonal Antibody Conjugated 5 for Oncology 93

RDX-002 94

Recombinant Proteins for Undisclosed Indication 95

SAR-088 96

SAR-110068 97

SAR-131675 98

SAR-156497 99

SAR-184841 100

SAR-216471 101

SAR-224 102

SAR-244181 103

SAR-296968 104

SAR-396049 105

Small Molecules 1 for Tuberculosis 106

Small Molecules for Malaria 107

Small Molecules to Inhibit DGAT-1 for Metabolic Disorders 108

Small Molecules to Inhibit PI3K Beta for Oncology 109

Vasculotide 110

Labyrinthopeptine A1 111

Monoclonal Antibodies for Infectious Disease 112

SAR-405 113

Small Molecule 4 for Tuberculosis 114

Small Molecule for Calcific Aortic Valve Stenosis 115

Small Molecule for Dilated Cardiomyopathy 116

Small Molecule for Duchenne Muscular Dystrophy 117

Small Molecules 2 for Tuberculosis 118

Small Molecules 3 for Tuberculosis 119

Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Diabetes 120

Small Molecules to Inhibit Protein Kinase for Multiple Undisclosed Indications 121

Small Molecules to Inhibit Protein Kinase for Undisclosed Indication 122

Sanofi-Pipeline Analysis 123

Sanofi-Pipeline Products by Target 123

Sanofi-Pipeline Products by Route of Administration 127

Sanofi-Pipeline Products by Molecule Type 128

Sanofi-Pipeline Products by Mechanism of Action 129

Sanofi-Recent Pipeline Updates 133

Sanofi-Dormant Projects 161

Sanofi-Discontinued Pipeline Products 165

Discontinued Pipeline Product Profiles 167

Sanofi-Locations And Subsidiaries 177

Head Office 177

Other Locations & Subsidiaries 177

Sanofi-Key Manufacturing Facilities 195

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Tables

Sanofi, Key Information 13

Sanofi, Key Facts 13

Sanofi-Pipeline by Indication, 2015 16

Sanofi-Pipeline by Stage of Development, 2015 21

Sanofi-Monotherapy Products in Pipeline, 2015 22

Sanofi-Combination Treatment Modalities in Pipeline, 2015 23

Sanofi-Partnered Products in Pipeline, 2015 24

Sanofi-Partnered Products/ Combination Treatment Modalities, 2015 25

Sanofi-Out-Licensed Products in Pipeline, 2015 26

Sanofi-Out-Licensed Products/ Combination Treatment Modalities, 2015 27

Sanofi-Pre-Registration, 2015 28

Sanofi-Filing rejected/Withdrawn, 2015 29

Sanofi-Phase III, 2015 30

Sanofi-Phase II, 2015 31

Sanofi-Phase I, 2015 32

Sanofi-Preclinical, 2015 34

Sanofi-Discovery, 2015 36

Sanofi-Pipeline by Target, 2015 130

Sanofi-Pipeline by Route of Administration, 2015 134

Sanofi-Pipeline by Molecule Type, 2015 135

Sanofi-Pipeline Products by Mechanism of Action, 2015 137

Sanofi-Recent Pipeline Updates, 2015 140

Sanofi-Dormant Developmental Projects,2015 168

Sanofi-Discontinued Pipeline Products, 2015 172

Sanofi, Other Locations 184

Sanofi, Subsidiaries 184

Sanofi, Key Manufacturing Facilities 202

List of Figures

Sanofi-Pipeline by Top 10 Indication, 2015 15

Sanofi-Pipeline by Stage of Development, 2015 21

Sanofi-Monotherapy Products in Pipeline, 2015 22

Sanofi-Combination Treatment Modalities in Pipeline, 2015 23

Sanofi-Partnered Products in Pipeline, 2015 24

Sanofi-Out-Licensed Products in Pipeline, 2015 26

Sanofi-Pipeline by Top 10 Target, 2015 130

Sanofi-Pipeline by Top 10 Route of Administration, 2015 134

Sanofi-Pipeline by Top 10 Molecule Type, 2015 135

Sanofi-Pipeline Products by Top 10 Mechanism of Action, 2015 136

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Sanofi; Sanofi - Key Therapeutics; Sanofi - Pipeline Overview and Promising Molecules; Sanofi - News; Sanofi - Latest Updates; Sanofi - Pipeline; Sanofi - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]